tiprankstipranks
Trending News
More News >
Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
US Market
Advertisement

Cartesian Therapeutics (RNAC) Income Statement

Compare
1,114 Followers

Cartesian Therapeutics Income Statement

Last quarter (Q1 2025), Cartesian Therapeutics's total revenue was $1.10M, a decrease of -81.16% from the same quarter last year. In Q1, Cartesian Therapeutics's net income was $-17.71M. See Cartesian Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 38.91M$ 26.00M$ 110.78M$ 85.08M$ 16.60M
Gross Profit
$ 38.91M$ 24.45M$ 108.74M$ 85.08M$ 16.60M
Operating Expenses
$ 82.81M$ 110.87M$ 96.24M$ 89.67M$ 73.42M
Depreciation and Amortization
$ 0.00$ 843.00K$ 2.04M$ 1.72M$ 1.73M
EBITDA
$ -77.14M$ -235.06M$ 39.84M$ -5.16M$ -65.59M
Operating Income
$ -43.90M$ -86.42M$ 14.54M$ -4.60M$ -56.82M
Other Income/Expenses
$ -33.24M$ -152.29M$ 20.23M$ -5.12M$ -12.05M
Pretax Income
$ -77.14M$ -238.71M$ 34.77M$ -9.72M$ -68.88M
Net Income
$ -77.42M$ -219.71M$ 35.38M$ -25.69M$ -68.88M
Per Share Metrics
Basic EPS
$ -2.99$ -49.76$ 7.20$ -6.74$ -20.42
Diluted EPS
$ -0.50$ -49.76$ 3.00$ -6.74$ -20.42
Weighted Average Shares Outstanding
25.90M 5.17M---
Weighted Average Shares Outstanding (Diluted)
25.90M 5.17M---
Currency in USD

Cartesian Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis